Loading song details...
AGDD 2024 D1S01 Keynote Address
No description available.
MP3 Download
Video Download
Related Songs
17:29
AGDD 2024 D1S01 Keynote Address
15:29
AGDD 2024 D1S11 Orally Inhaled Drug Product PSGs Considerations For Using Modeling And Sim
9:20
AGDD 2024 D2S10 1 Analysis Of First Cycle BE Adequacy And Major Deficiencies Encountered
12:28
AGDD 2024 D1S15 Approaches To Analyzing Comparative Use Human Factors Studies
22:07
AGDD 2024 D2S06 Emerging Generic Oligonucleotides Challenges And Progress
13:29
AGDD 2024 D1S03 Nano Size Complex Products In Vitro Release Testing IVRT
22:53
AGDD 2024 D1S10 Orally Inhaled Drug Product PSGs General Considerations Using The Alternative
17:12
AGDD 2024 D1S07 Enhanced Understanding Of Structure Performance Relationship Using Modeling
5:24
AGDD 2024 D1S16 Closing Remarks From Day One
22:47
AGDD 2024 D1S14 Drug Device Combination Products A New Methodology For Evaluation
28:49
AGDD 2024 D1S05 Q A Discussion Panel 1
21:06
AGDD 2024 D2S09 Guidance For Industry Content And Format Of Composition Statement
14:39
AGDD 2024 D1S06 Current Trends In Product Specific Guidance PSG Development Revisions For
7:07
AGDD 2024 D2S14 Closing Remarks
21:59
AGDD 2024 D2S02 Quality Considerations For First Generic Oral Liquids
15:57
AGDD 2024 D1S04 Application Of Adaptive Perfusion As In Vitro Release Testing Method
27:38
AGDD 2024 D2S04 Q A Discussion Panel 1
11:54
AGDD 2024 D2S05 1 Totality Of Evidence Including Physiologically Based Pharmacokinetic Modeling
18:42
AGDD 2024 D1S08 Approaches For Evaluation Of Formulation Differences On Performance Topical
20:42